Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum

Folia Microbiologica

Volumn 57, Issue 5, 2012, Pages 415-419

  Fialova L ^a   Svarcova J ^a   Bartos, A ^b,c   Malbohan, I ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; NEUROFILAMENT M PROTEIN; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L; TAU PROTEIN;

ADULT; AGED; ANTIBODY AFFINITY; ARTICLE; BLOOD; CEREBROSPINAL FLUID; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY AFFINITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; TAU PROTEINS;

EID: 84865516846     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12223-012-0105-x     Document Type: Article

References (30)

1. Avrameas S, Ternynck T (1993) The natural autoantibodies system: between hypotheses and facts. Mol Immunol 30: 1133-1142.
2. Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pit'ha J (2007a) Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 254: 20-25.
3. Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pitha J (2007b) Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 116: 100-107.
4. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139-145.
5. Cui Z, Zhao MH (2005) Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. Clin Immunol 116: 77-82.
6. de Souza VA, Pannuti CS, Sumita LM, de Andrade Junior HF (1997) Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J Med Virol 52: 275-279.
7. Fialova L, Bartos A, Soukupova J, Svarcova J, Ridzon P, Malbohan I (2009) Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases. Folia Biol (Praha) 55: 23-26.
8. Flori P, Tardy L, Patural H, Bellete B, Varlet MN, Hafid J, Raberin H, Sung RT (2004) Reliability of immunoglobulin G antitoxoplasma avidity test and effects of treatment on avidity indexes of infants and pregnant women. Clin Diagn Lab Immunol 11: 669-674.
9. Giovannoni G, Chapman MD, Thompson EJ (2006) The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders. J Neuroimmunol 180: 29-32.
10. Huizinga R, Heijmans N, Schubert P, Gschmeissner S, t Hart BA, Herrmann H, Amor S (2007) Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 66: 295-304.
11. Ilyas AA, Chen ZW, Cook SD (2003) Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 139: 76-80.
12. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L (2006) Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 20: 127-132.
13. Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, de Bustos F, Zurdo JM, Alonso H, Puertas I, Barcenilla B, Sayed Y, Cabrera-Valdivia F (2005) Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 111: 114-117.
14. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
15. Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, Keir G, Thompson EJ, Giovannoni G (2005) Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 11: 532-536.
16. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
17. Martinez-Yelamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T (2004) Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 363: 14-17.
18. Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, Dussart P (2005a) Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample. J Clin Microbiol 43: 2793-2797.
19. Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, Dussart P (2005b) Use of four dengue virus antigens for determination of dengue immune status by enzyme-linked immunosorbent assay of immunoglobulin G avidity. J Clin Microbiol 43: 5784-5786.
20. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127.
21. Narita M, Yamada S, Matsuzono Y, Itakura O, Togashi T, Kikuta H (1996) Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection. Clin Diagn Lab Immunol 3: 211-215.
22. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.
23. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M (2006) Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 410: 90-93.
24. Silber E, Semra YK, Gregson NA, Sharief MK (2002) Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 58: 1372-1381.
25. Skoda D, Kranda K, Bojar M, Glosova L, Baurle J, Kenney J, Romportl D, Pelichovska M, Cvachovec K (2006) Antibody formation against beta-tubulin class III in response to brain trauma. Brain Res Bull 68: 213-216.
26. Sussmuth SD, Reiber H, Tumani H (2001) Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 300: 95-98.
27. Svarcova J, Fialova L, Bartos A, Steinbachova M, Malbohan I (2008) Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. Eur J Neurol 15: 1173-1179.
28. Vyshkina T, Kalman B (2008) Autoantibodies and neurodegeneration in multiple sclerosis. Lab Invest 88: 796-807.
29. Zaffaroni M (2003) Biological indicators of the neurodegenerative phase of multiple sclerosis. Neurol Sci 24(Suppl 5): S279-282.
30. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM (2007) Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 14: 1329-1333.